Peripheral T-Cell Non-Hodgkin's Lymphoma

      T-cell non-Hodgkin's lymphoma (T-NHL) are uncommon malignancies accounting for 10% to 15% of all NHL. Geographic variation has been well documented, but the geographic variation may reflect exposure to specific pathogenic viruses, such as Epstein Barr Virus and Human T-cell leukemia virus-1 in Asian countries. The World Health Organization classification specifies 16 major subtypes of T-NHL. Each of the major subtype of peripheral T-NHL has unique characteristics and are addressed separately in this article.


      To read this article in full you will need to make a payment
      Purchase one-time access
      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
      Content published before 2002 is available via pay-per-view purchase only.
      Subscribe to Hematology/Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma: the Non-Hodgkin's Lymphoma Classification Project.
        Blood. 1997; 89: 3909-3918
        • Anderson J.R.
        • Armitage J.O.
        • Weisenburger D.D.
        • et al.
        Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations.
        Ann Oncol. 1998; 9: 717-720
        • Takatsuki K.
        • Matsuoka M.
        • Yamaguchi K.
        Adult T-cell leukemia in Japan.
        J Acquir Immune Defic Syndr Hum Retrovirol. 1996; 13: S15-S19
        • Quintanilla-Martinez L.
        • Kumar S.
        • Fend F.
        • et al.
        Fulminant EBV + T-cell lymphoproliferative disorders following acute/chronic EBV infection: a distinct clinicopathologic syndrome.
        Blood. 2000; 96: 443-451
        • Jaffe E.S.
        • Harris N.L.
        • Stein H.
        • et al.
        Pathology and genetics of tumours of haematopoietic and lymphoid tissues.
        IARC Press, Lyon (France)2001
        • Rudiger T.
        • Weisenburger D.D.
        • Anderson J.R.
        • et al.
        Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.
        Ann Oncol. 2002; 13: 140-149
        • Gallamini A.
        • Stelitano C.
        • Calvi R.
        • et al.
        Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicenter clinical study.
        Blood. 2004; 103: 2474-2479
        • Savage K.J.
        • Chhanabhai M.
        • Gascoyne R.D.
        • et al.
        Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification.
        Ann Oncol. 2004; 15: 1467-1475
        • Escalon M.P.
        • Liu N.S.
        • Yang Y.
        • et al.
        Prognostic factors and treatment of patients with T-cell non-Hodgkin's lymphoma.
        Cancer. 2005; 103: 2091-2098
        • Gisselbrecht C.
        • Gaulard P.
        • Lepage E.
        • et al.
        Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas.
        Blood. 1998; 92: 76-82
        • Tsimberidou A.M.
        • Giles F.
        • Duvic M.
        • et al.
        Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series.
        Cancer. 2004; 100: 342-349
        • Yamaguchi M.
        • Kotani T.
        • Nakamure Y.
        • et al.
        Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide.
        Int J Hematol. 2006; 83: 450-453
        • Sallah S.
        • Wan J.Y.
        • Nguyen N.P.
        Treatment of refractory T-cell malignancies using gemcitabine.
        Br J Haematol. 2001; 113: 185-187
        • Zinzani P.L.
        • Musuraca G.
        • Tani M.
        • et al.
        Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
        J Clin Oncol. 2007; 25: 4293-4297
        • Dang N.H.
        • Pro B.
        • Hagemeiser F.B.
        • et al.
        Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin's lymphoma.
        Br J Haematol. 2007; 136: 439-447
        • Zinzani P.L.
        • Alinari L.
        • Tani M.
        • et al.
        Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma.
        Haematologica. 2005; 90: 702-703
        • Piekarz R.L.
        • Frye R.
        • Turner M.
        • et al.
        Responses and molecular markers in patients with peripheral T-cell lymphoma treated on a phase II trial of depsipeptide, FK228.
        J Clin Oncol. 2005; 23: 3061a
        • Olsen E.A.
        • Kim Y.H.
        • Kuzel T.M.
        • et al.
        Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
        J Clin Oncol. 2007; 25: 3109-3115
        • O'Connor O.A.
        • Hamlin P.A.
        • Gerecitano J.
        • et al.
        Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-cell lymphomas: results of the MSKCC phase I/II experience.
        Blood. 2006; 108: 400a
        • Kewalramani T.
        • Zelenetz A.D.
        • Teruya-Feldstein J.
        • et al.
        Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
        Br J Haematol. 2006; 134: 202-207
        • Chen A.I.
        • McMillan A.
        • Nerin R.S.
        • et al.
        Long term results of autologous hematopoietic cell transplantation (AHCT) for peripheral T-cell lymphoma: the Stanford experience.
        Blood. 2007; 110: 1906a
        • Rodriguez J.
        • Conde E.
        • Gutierrez A.
        • et al.
        Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo-Study Group.
        Eur J Haematol. 2007; 79: 3-38
        • Reimer P.
        • Schertlin T.
        • Rudinger T.
        • et al.
        Myeloablative radiochemotherpy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study.
        Hematol J. 2004; 5: 304-311
        • Le Gouill S.
        • Milpied N.
        • Buzyn A.
        • et al.
        Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societé Francaise of Greffe de Moelle et de Therapie Cellulaire.
        J Clin Oncol. 2008; 26: 2264-2271
        • Corradini P.
        • Dodero A.
        • Zallio F.
        • et al.
        Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
        J Clin Oncol. 2004; 22: 2172-2176
        • Vose J.M.
        International Peripheral T-cell Lymphoma Study: clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracylines.
        Blood. 2005; 106: 811a
        • Siegert W.
        • Nerl C.
        • Agthe A.
        • et al.
        Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation: the Kiel Lymphoma Study Group.
        Ann Oncol. 1995; 6: 659-664
        • Reiser M.
        • Josting A.
        • Soltani M.
        • et al.
        T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors.
        Leuk Lymphoma. 2002; 43: 805-811
        • Mourad N.
        • Mounier N.
        • Briere J.
        • et al.
        Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials.
        Blood. 2008; 111: 4463-4470
        • Advani R.
        • Horowitz S.
        • Zelenetz A.
        • et al.
        Angioimmunoblastic T-cell lymphoma: treatment experience with cyclosporine.
        Leuk Lymphoma. 2007; 48: 521-525
        • Quintini G.
        • Iannitto E.
        • Barbera V.
        • et al.
        Response to low-dose oral methotrexate and prednisone in two patients with angio-immunoblastic lymphadenopathy-type T-cell lymphoma.
        Hematol J. 2001; 2: 393-395
        • Falini B.
        • Pileri S.
        • Zinzani P.L.
        • et al.
        ALK+ lymphoma: clinico-pathological findings and outcome.
        Blood. 1999; 93: 2697-2706
        • Weisenburger D.D.
        • Gordon B.G.
        • Vose J.M.
        • et al.
        Occurrence of the t(2;5)(p23p35) in non-Hodgkin's lymphoma.
        Blood. 1996; 87: 3860-3868
        • Zinzani P.L.
        • Bendandi M.
        • Martelli M.
        • et al.
        Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients.
        J Clin Oncol. 1996; 14: 955-962
        • Jaffe E.S.
        • Chan J.K.
        • Su I.J.
        • et al.
        Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas: definitions, differential diagnosis, and epidemiology.
        Am J Surg Pathol. 1996; 20: 103-111
        • Cheung M.M.
        • Chan J.K.
        • Lau W.H.
        • et al.
        Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunphenotype, and treatment outcome of 113 patients.
        J Clin Oncol. 1998; 16: 70-77
        • Kim G.E.
        • Lee S.W.
        • Chang S.K.
        • et al.
        Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck.
        Radiother Oncol. 2001; 61: 261-269
        • Belhadj K.
        • Reyes F.
        • Farcet J.P.
        • et al.
        Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients.
        Blood. 2003; 102: 4261-4269
        • Howell W.M.
        • Leung S.T.
        • Jones D.B.
        • et al.
        HLA-DRB, DQA, and DQB polymorphism in celiac disease and Enteropathy-associated T-cell lymphoma: common features and additional risk factors for malignancy.
        Hum Immunol. 1995; 43: 29-37
        • Salhany K.E.
        • Macon W.R.
        • Choi J.K.
        • et al.
        Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes.
        Am J Surg Pathol. 1998; 22: 881-893
        • Willemze R.
        • Jansen P.M.
        • Cerroni L.
        • et al.
        Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 patients.
        Blood. 2008; 111: 838-845
        • Shimoyama M.
        Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984–1987).
        Br J Haematol. 1991; 79: 428-437
        • Chen Y.C.
        • Wang C.H.
        • Su I.J.
        • et al.
        Infection of human T-cell leukemia virus type I and development of human T-cell leukemia lymphoma in patients with hematologic neoplasms: a possible linkage to blood transfusion.
        Blood. 1989; 74: 388-394
        • Ishitsuka K.
        • Tamura K.
        Treatment of adult T-cell leukemia/lymphoma: past, present, and future.
        Eur J Haematol. 2008; 80: 185-196
        • d'Amore F.
        • Radford J.
        • Jerkeman M.
        • et al.
        Zanolimumab (HuMax CD4), a fully human monoclonal antibody: efficacy and safety in patients with relapsed or treatment-refractory non-cutaneous CD4+ T-cell lymphoma.
        Blood. 2007; 110: 3409a
        • Casale D.A.
        • Barlett N.L.
        • Hurd D.D.
        • et al.
        A phase I open label dose escalation study to evaluate MEDI-507 in patients with CD2-positive T-cell lymphoma/leukemia.
        Blood. 2006; 108: 2727a
        • Uike N.
        • Tsukasaki K.
        • Utsunomiya A.
        • et al.
        Phase I study of KW-0761, a humanized anti-CCR4 antibody in patients with relapsed or refractory adult T-cell leukemia/lymphoma (ATLL) and peripheral T-cell lymphoma (PTCL): preliminary results.
        Blood. 2007; 110: 4492a
        • Forero-Torres A.
        • Bernstein S.
        • Gopal A.
        • et al.
        SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma.
        Blood. 2004; 104: 2637a
        • Ansell S.M.
        • Byrd J.C.
        • Horwitz S.M.
        • et al.
        Phase I/II open-label dose-escalating study of MDX-060 administered weekly for 4 weeks in subjects with refractory/relapsed CD30 positive lymphoma.
        Blood. 2004; 104: 2636a
        • Feldman A.L.
        • Sun D.X.
        • Law M.E.
        • et al.
        Syk tyrosine kinase is overexpressed in the majority of peripheral T- and NK-cell lymphomas, and represents a potential therapeutic target.
        Blood. 2007; 110: 690a